



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Vonoprazan fumarate/amoxicillin hydrate/clarithromycin

Vonoprazan fumarate/amoxicillin hydrate/metronidazole

March 19, 2019

Non-proprietary name

Vonoprazan fumarate/amoxicillin hydrate/clarithromycin

Vonoprazan fumarate/amoxicillin hydrate/metronidazole

Safety measure

Precautions should be revised in the package insert.

For vonoprazan fumarate, a Clinically Significant Adverse Reactions subsection should be newly added to the Adverse Reactions section and the following language should be included (revised language is underlined):

Toxic epidermal necrolysis (TEN), oculomucocutaneous syndrome (Stevens-Johnson syndrome), erythema multiforme:

Toxic epidermal necrolysis, oculomucocutaneous syndrome, or erythema multiforme may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp